@article{99caaffc6da6495d8f1ab58c413f3fa6,
title = "Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): Consensus statement",
abstract = "Multiple myeloma is a neoplastic plasma cell dyscrasia that on a yearly basis affects nearly 17,000 individuals and kills more than 11,000. Although no cure exists, many effective treatments are available that prolong survival and improve the quality of life of patients with this disease. The purpose of this consensus is to offer a simplified, evidence-based algorithm of decision making for patients with newly diagnosed myeloma. In cases in which evidence is lacking, our team of 18 Mayo Clinic myeloma experts reached a consensus on what therapy could generally be recommended. The focal point of our strategy revolves around risk stratification. Although a multitude of risk factors have been identified throughout the years, including age, tumor burden, renal function, lactate dehydrogenase, β2-microglobulin, and serum albumin, our group has now recognized and endorsed a genetic stratification and patient functional status for treatment.",
author = "Angela Dispenzieri and Rajkumar, {S. Vincent} and Gertz, {Morie A.} and Rafael Fonseca and Lacy, {Martha Q.} and Bergsagel, {P. Leif} and Kyle, {Robert A.} and Greipp, {Philip R.} and Witzig, {Thomas E.} and Reeder, {Craig B.} and Lust, {John A.} and Russell, {Stephen J.} and Hayman, {Suzanne R.} and Vivek Roy and Shaji Kumar and Zeldenrust, {Steven R.} and Dalton, {Robert J.} and Stewart, {A. Keith}",
note = "Funding Information: In one small randomized trial of 85 patients, a survival advantage was found at 54 months in favor of the interferon alfa arm (33% vs 12% alive), but this difference did not persist with longer follow-up. 202 The benefit of interferon alfa was also supported by a study from the European Group for Blood and Marrow Transplantation registry. In this retrospective review of nearly 900 patients, just more than half of the patients received interferon alfa. The 2 groups were poorly matched, with the interferon-treated patients being of significantly lower risk. 203 Overall survival was better in the patients who received interferon (78 vs 47 months; P =.007). Paradoxically, the partial response group had a better OS than the CR group, and there was a greater survival benefit for patients who achieved a partial response (97 vs 46 months for interferon vs no interferon; P =.03) rather than CR (64 vs 51 months; P =.1). ",
year = "2007",
month = mar,
doi = "10.4065/82.3.323",
language = "English (US)",
volume = "82",
pages = "323--341",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "3",
}